Form 4: Tenax Therapeutics Director Acquires 100,000 Stock Options
SEC Form 4
June Sherie Almenoff, a director at Tenax Therapeutics, acquired 100,000 stock options on December 10, 2024.
Summary
- June Sherie Almenoff, a director of Tenax Therapeutics, acquired 100,000 stock options on December 10, 2024.
- These options have an exercise price of $5.94 per share and expire on December 10, 2034.
- The director also holds previously reported stock options that were adjusted to reflect stock splits on January 4, 2023 and January 2, 2024.
- These adjustments include options originally for 6,250 shares at $2.00 per share and 5,000 shares at $0.62 per share.
Sentiment
Score: 6
Explanation: The document is a routine filing related to stock option grants, which is neither particularly positive nor negative. It indicates a director's continued involvement with the company.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders reporting changes in their beneficial ownership of company securities.
Comparison to Industry Standards
- Stock option grants to directors are a common practice in publicly traded companies as part of their compensation packages.
- The exercise price and expiration dates are typical for such grants.
- Stock splits are also a common corporate action, and adjustments to option holdings are standard procedure.
Stakeholder Impact
- The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/10/2022 | Date of previously reported stock options with an exercise price of $2.00 per share, later adjusted for stock splits. |
| 06/09/2023 | Date of previously reported stock options with an exercise price of $0.62 per share, later adjusted for stock splits. |
| 12/10/2024 | Date of the acquisition of 100,000 stock options at an exercise price of $5.94 per share. |
| 12/10/2025 | Date the 100,000 stock options become exercisable. |
| 12/10/2034 | Expiration date of the 100,000 stock options. |
Keywords
stock options, director, Tenax Therapeutics, insider trading, equity, TENX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.